Comparison of Myoinositol and Metformin in PCO
Maneno muhimu
Kikemikali
Maelezo
PCOS is a common endocrine disorder in women of reproductive age associated with insulin resistance. Metformin and Myo-inositol being insulin sensitizers improve biochemical parameters. it is aimed to compare the effect of myoinositol and metformin in the resumption of the spontaneous menstrual cycle in patients diagnosed with PCOS or having oligo/amenorrhea, reduction in weight and BMI, Improvement in the biochemical and clinical profile of patients with the polycystic syndrome.
Inclusion criteria: will be based on the Rotterdam criteria of diagnosing PCO. Patients presenting with a history of secondary amenorrhea, irregular menstrual cycle, oligomenorrhea, weight gain, hirsutism, and already diagnosed cases of PCO will be included in this group.
Patients with history of Hyperprolactinemia, Cushing's disease, Hypothyroidism/ Hyperthyroidism, Pregnancy and nursing, Established type 1 or type 2 diabetes mellitus, Any history of drug intake e.g. anti-diabetic or estrogen and progesterone, History of treatment for the same complaint taken in the last 3 months, Unable to come for regular follow-ups, Any pathological cause of bleeding e.g. Fibroid, Polyp, Cervical pathology and known allergic to these drugs would be excluded.
Tarehe
| Imethibitishwa Mwisho: | 11/30/2019 |
| Iliyowasilishwa Kwanza: | 10/21/2019 |
| Uandikishaji uliokadiriwa Uliwasilishwa: | 12/16/2019 |
| Iliyotumwa Kwanza: | 12/17/2019 |
| Sasisho la Mwisho Liliwasilishwa: | 12/16/2019 |
| Sasisho la Mwisho Lilichapishwa: | 12/18/2019 |
| Tarehe halisi ya kuanza kwa masomo: | 12/31/2019 |
| Tarehe ya Kukamilisha Msingi iliyokadiriwa: | 12/30/2020 |
| Tarehe ya Kukamilisha Utafiti: | 02/24/2021 |
Hali au ugonjwa
Uingiliaji / matibabu
Drug: Metformin Hydrochloride
Drug: Myo-inositol
Awamu
Vikundi vya Arm
| Mkono | Uingiliaji / matibabu |
|---|---|
| Experimental: GROUP A ( metformin 500 mg TDS) Life style modifications, Weight reduction and folic acid will be prescribed with metformin 500 mg three times a day | |
| Experimental: GROUP B( myoinositol 2000mg x BD ) Life style modifications, Weight reduction and folic acid will be prescribed with myoinositol 2000 mg two times a day | |
| Experimental: GROUP C.(both metformin,& myoinositol) Life style modifications, Weight reduction and folic acid will be prescribed with both metformin,& myoinositol three and two times a day respectively |
Vigezo vya Kustahiki
| Zama zinazostahiki Kujifunza | 16 Years Kwa 16 Years |
| Jinsia Inastahiki Kujifunza | Female |
| Hupokea Wajitolea wa Afya | Ndio |
| Vigezo | Inclusion Criteria: It will be based on the Rotterdam criteria of diagnosing PCO. Patients presenting with a history of secondary amenorrhea, irregular menstrual cycle, oligomenorrhea, weight gain, hirsutism, and already diagnosed cases of PCO will be included in this group. Exclusion Criteria: - Hyperprolactinemia - Cushing's disease - Hypothyroidism/ Hyperthyroidism - Pregnancy and nursing - Established type 1 or type 2 diabetes mellitus - Any history of drug intake e.g. anti-diabetic or estrogen and progesterone - History of treatment for the same complaint taken in the last 3 months - Unable to come for regular follow-ups - Any pathological cause of bleeding e.g. Fibroid, Polyp, Cervical pathology - Known allergic to these drugs |
Matokeo
Hatua za Matokeo ya Msingi
1. Menstrual cycle regulation [Follow up at 3rd and 6th months]
2. change in weight [Follow up at 3rd and 6th months]
Hatua za Matokeo ya Sekondari
1. Pregnancy / Miscarriage [1 year]
